Key takeaway: SR&ED for Canadian subsidiaries of a foreign parent usually runs at a different, worse rate than the version of the program most founders picture. The enhanced 35% refundable rate is reserved for Canadian-controlled private corporations and, since late 2024, listed Canadian public corporations — private, foreign-controlled companies fall outside both categories, into a bucket taxed at 15% with no refund at all. On $2 million of eligible spend, that's roughly $700,000 in refundable cash for a CCPC versus a $300,000 non-refundable credit that a pre-revenue subsidiary often can't even use. Ownership structure, not the engineering, is what decides which one you get.
Ask a founder whether their company is a Canadian-controlled private corporation and most say yes without checking. They're incorporated in Canada, the office is in Toronto or Vancouver, the team files a T2 every year — sounds Canadian-controlled. Then a US fund leads the Series A, takes a board seat and a majority stake, and nobody revisits the question until the SR&ED claim comes back smaller than the spreadsheet said it would.
This post covers what actually determines your SR&ED rate, why a foreign-owned subsidiary usually lands in the worst-paying tier of the program rather than the best, what the rate difference costs in real dollars, and the handful of situations where a foreign-backed company still keeps the enhanced rate. If you haven't claimed SR&ED at all yet, our complete SR&ED guide covers the program from the ground up; this post assumes you know the basics and goes straight at the ownership-specific mechanics.
Does a Canadian subsidiary of a foreign company qualify for SR&ED
Yes — SR&ED eligibility itself doesn't care who owns you. The two-part test is about the work: does it resolve genuine scientific or technological uncertainty through systematic investigation, and any corporation doing that kind of work in Canada can file a claim. What ownership decides isn't whether you qualify. It decides which of two very different rate schedules you qualify at.
That's the distinction that trips people up. A Canadian subsidiary building genuinely novel software has exactly the same technical claim as an independent Canadian startup doing identical work. The eligibility test doesn't ask who's on your cap table. The rate table does.
Why CCPC status is the whole ballgame
Here's the CRA's own rate table, and it's worth sitting with for a second: most Canadian-controlled private corporations earn a refundable ITC at the enhanced rate of 35% on qualified expenditures up to the expenditure limit — currently $6 million for tax years beginning after December 15, 2024. For tax years beginning after that same date, eligible Canadian public corporations can earn that identical 35% rate too. Everyone else — the CRA's own words are "all other corporations not included above" — earns 15%, and it's non-refundable.
Two tiers, one program. The gap between them isn't a rounding error: 35% refundable versus 15% non-refundable is the difference between cash landing in your bank account and a credit that only offsets tax you'd otherwise owe — tax a pre-revenue or early-revenue subsidiary frequently doesn't owe much of in the first place.
So who's in the top tier? CCPCs, plus (since the 2024 rule change) a narrow category called an eligible Canadian public corporation. An ECPC, per the CRA's own definition, "is a public corporation, listed on a designated stock exchange, that is resident in Canada" and "not controlled, directly or indirectly in any manner, by one or more non-resident persons." Read that twice if you're a private, VC-backed subsidiary: you're not listed on an exchange, so the ECPC door is closed to you regardless of who owns you. The only door left is CCPC status. And CCPC status runs into the same wall the ECPC definition states outright — control by non-residents is exactly the thing that keeps a company out of the enhanced-rate tiers the program is built around.
A privately held Canadian company that's majority-owned or controlled by a US (or any non-resident) parent generally isn't a CCPC, for the same reason it isn't an ECPC: non-resident control. That's not an SR&ED-specific quirk — it's the general Canadian tax-law concept of Canadian control, and SR&ED just happens to be where the consequence is largest. We're not going to cite an exact statutory test here, because the CRA's SR&ED pages don't spell out the CCPC control test the way they spell out the ECPC one, and this is exactly the kind of specific we'd rather flag as "talk to your accountant" than guess at. What the CRA's rate table does spell out, precisely, is what happens once you land outside both categories: 15%, non-refundable, full stop.
What the 15% non-refundable rate actually costs you
On $2 million of eligible R&D spend, the two rates land in completely different universes: a CCPC gets $700,000 in cash, a non-CCPC gets a $300,000 credit that might sit unused for years. Here's where each number comes from.
A CCPC at that spend level, under the expenditure limit, earns a 35% ITC — $700,000 — and the portion earned on current expenditures up to the limit is 100% refundable. That's $700,000 in cash, whether or not the company owes a dollar of tax.
A foreign-controlled private subsidiary doing the identical $2 million of work earns a 15% ITC — $300,000 — and it's non-refundable. Non-refundable means it reduces tax payable and nothing else. A subsidiary running at a loss, which describes most companies doing serious R&D, has no tax payable to reduce. The credit doesn't vanish outright — unused amounts can typically be carried forward — but "carry it forward and hope you're profitable someday" is a very different outcome from a cheque this year, and it's the reason so many founders assume their SR&ED claim is worth far more than what actually shows up.
$700,000 versus a deferred $300,000 on the same engineering spend. Same code, same team, same eligibility test passed — a different owner on the cap table is the entire reason for the gap.
The moment this usually happens: after the round, not before
This usually happens after a financing round or acquisition, not from day one — control shifts to a non-resident investor or parent, and CCPC status can go with it without anyone flagging the connection. Almost nobody starts a company as a foreign-controlled subsidiary on purpose; it happens in a financing event founders were focused on for entirely different reasons.
A Canadian startup incorporates, builds for a couple of years as a CCPC, claims SR&ED at the 35% rate the whole time — completely correctly. Then it raises a priced Series A led by a US venture fund that takes a majority stake and board control as a condition of the deal. Nothing about the engineering changed. Nothing about the office, the team, or the product changed. But if that round shifted control to a non-resident, the company's CCPC status may have gone with it, and the SR&ED math for that tax year onward looks completely different from the year before — a detail that shows up on nobody's term sheet checklist, because it isn't the lawyers' or the investors' job to flag it. It's the kind of thing a claim preparer should be asking about at year-end, not discovering when a rate that used to be 35% comes back as 15%.
The same thing happens through acquisition, not just financing: a Canadian R&D team gets folded into a US parent as a wholly owned subsidiary, keeps doing the identical technical work under the new ownership, and keeps filing SR&ED — at a rate that just moved to a different tier. If your company was ever independently Canadian-controlled and has since been acquired by, or taken majority investment from, an entity outside Canada, that's the trigger to check.
Who should actually check their status — and who can skip this
Skip this if: you're bootstrapped or have raised only from Canadian angels and funds without giving up majority control, you're a Canadian-founded startup with a foreign parent that holds a minority, non-controlling stake, or you've never taken outside capital at all. None of that puts CCPC status in question on its own.
Check this if: a non-resident entity — a fund, a strategic acquirer, a parent company — holds a majority stake or otherwise controls board decisions; your Canadian entity was set up specifically as a subsidiary of a company headquartered elsewhere; or you've been through a financing round or acquisition since your last SR&ED claim and haven't specifically revisited CCPC status since. This is a legal and accounting determination, not something a blog post can resolve for your specific cap table — convertible instruments, side letters, and voting-versus-economic control can all change the answer, which is exactly why it's worth a direct conversation with whoever prepares your claim rather than a guess.
It's not just the rate — refundability compounds the hit
A non-refundable credit only offsets tax you actually owe — and most R&D-heavy subsidiaries, foreign-owned or not, are burning cash and owe little to nothing. The rate gap gets most of the attention, but refundability is quietly doing more damage than the headline percentages suggest.
A profitable, tax-paying company can eventually use a non-refundable 15% credit — it just takes longer to realize the value, since it only offsets tax otherwise owed. A subsidiary still burning cash on R&D, which is most of them, gets far less practical benefit from a non-refundable credit than a refundable one, right when cash actually matters. That's the part of this that's easy to miss if you're only comparing rate percentages: 35% versus 15% understates the real gap once you account for the fact that one version pays out as cash almost immediately and the other might not pay out in any useful timeframe at all.
What doesn't change, regardless of ownership
Two things stay identical no matter who controls your company, and they're worth being explicit about so this doesn't read as "foreign-owned companies shouldn't bother."
The eligibility test doesn't change. The same two-part test — technological uncertainty, resolved through systematic investigation — applies to every claimant regardless of ownership. A foreign-controlled subsidiary doing real R&D in Canada is still doing eligible work; it's simply compensated for it differently.
The documentation burden doesn't change either. Whatever rate you land at, the CRA still wants the same kind of evidence: what was uncertain, what was tried, what the systematic investigation actually looked like. A lower rate is not a reason to under-invest in the claim itself — if anything, a 15% non-refundable credit that takes years to realize is even less forgiving of a sloppy claim that gets challenged, because there's less margin to begin with. If you haven't looked at what a CRA review actually involves, that risk doesn't shrink just because your rate did.
Provincial credits are a separate wrinkle worth a one-line flag rather than a full digression: each province sets its own rules on who can claim and whether its credit is refundable, so check your province separately rather than assuming it follows the federal tier. Provincial credits also reduce your federal base. See our breakdown of the federal-provincial "grind" rule for how that stacking actually works, since it isn't simple addition.
What Glauq does with this
Most SR&ED providers build their whole pitch around maximizing the rate you already know you get. We'd rather make sure you know which rate that is in the first place — a foreign-controlled subsidiary that assumes CCPC status and budgets a 35% refund is planning around a number that isn't real, and finding that out at filing time is a worse conversation than finding it out at term-sheet time. Glauq's documentation runs continuously from the tools your engineering team already uses regardless of your ownership structure, and a qualified, independent SR&ED expert reviews every claim — including confirming which rate tier actually applies to your specific corporate structure — before anything goes to the CRA. The fee is flat, not a percentage of a refund that might turn out to be far smaller than expected.
Frequently asked questions
Does a Canadian subsidiary of a US company qualify for SR&ED? Yes, for eligibility purposes — the two-part test looks at the work, not the ownership. What ownership changes is the rate: a private subsidiary controlled by a non-resident parent generally doesn't qualify as a CCPC or as an eligible Canadian public corporation, so it earns the basic 15% non-refundable rate rather than the enhanced 35% refundable rate.
What's the difference between the CCPC rate and the non-CCPC SR&ED rate? A CCPC earns a refundable 35% ITC on qualified expenditures up to the $6 million expenditure limit, with the credit on current expenditures up to that limit fully refundable. A company that's neither a CCPC nor an eligible Canadian public corporation earns 15%, non-refundable — it only offsets tax payable rather than paying out as cash.
Can a foreign VC investment cost us our SR&ED rate? It can, if the investment shifts control of your company to a non-resident. A minority, non-controlling investment generally doesn't put CCPC status at risk on its own. A majority stake or board control held by a non-resident fund is the scenario worth a direct conversation with your accountant, since the specific mechanics of control — voting rights, convertible instruments, side agreements — decide the answer for your particular cap table.
Does losing CCPC status affect whether our R&D is eligible for SR&ED, or just the rate? Just the rate. The eligibility test — technological uncertainty resolved through systematic investigation — is identical for every claimant. Ownership structure doesn't touch eligibility; it only determines which of the CRA's rate tiers your qualified expenditures land in.
Can an eligible Canadian public corporation get the enhanced SR&ED rate even with foreign investors? The ECPC category itself requires that the corporation be a public company listed on a designated stock exchange and not controlled, directly or indirectly, by non-residents — so foreign investors holding a controlling stake would still be disqualifying, the same way it would be for CCPC status. Most private, VC-backed subsidiaries aren't public or listed at all, so the ECPC route isn't available to them regardless of the control question.
We were a CCPC when we started but raised a foreign-led round since — do we need to redo past claims? No — a change in control affects the tax years going forward from when control changed, not claims already filed correctly under your prior status. It does mean checking, from the year control changed onward, which rate actually applied for each subsequent claim.
The engineering doesn't know or care who's on your cap table. The SR&ED rate table does. If your company has taken foreign investment, been acquired, or restructured since you last thought about CCPC status, that's worth confirming before your next claim gets built around a rate that quietly stopped applying.
See what your claim could be worth — estimate your refund or check your eligibility.